Snapshot

Lab equipment and instruments companies manufacture the physical hardware (mass spectrometers, chromatographs, centrifuges, sequencers, liquid handlers) and the consumables (reagents, flow cells, filters, columns) that every life science and analytical chemistry lab uses to run experiments, test products, and diagnose disease. The four companies here—Thermo Fisher Scientific (TMO), Danaher (DHR), Agilent Technologies (A), and Illumina (ILMN)—collectively generated approximately $77B in trailing revenue and command a combined market capitalization of roughly $371B. The business model across all four is a "razors and blades" structure: place instruments at a modest margin, then earn recurring revenue from consumables, reagents, service contracts, and replacement parts for the life of each instrument, typically 7–15 years.

Three diversified giants (TMO, DHR, A) and one genomics specialist (ILMN) sit in an oligopoly. Customers build entire workflows around a vendor's platform—sample prep, analysis software, regulatory validation—creating multi-year lock-in. The instruments are the foot in the door; the consumables are the business.

Market size: Mordor Intelligence (2025). Pharma R&D: Evaluate Pharma via BioSpace (2024). Company revenue and market caps: SEC filings and market data, Jun 2026.

The product & how money is made

Each company sells physical instruments plus the consumables and services those instruments require. The economics work in two phases.

Phase 1: Instrument placement (the "razor")

A lab buys or leases a major instrument—a mass spectrometer ($100K–$1M+), a DNA sequencer ($200K–$1M+), a liquid chromatography system ($50K–$300K), or a bioprocessing skid ($500K–$5M+). This is a capital expenditure for the customer. Instrument revenue is lumpy, cyclical, and lower-margin. It is also the smaller fraction of each company's revenue.

Phase 2: Consumables, reagents, and service (the "blades")

Once an instrument is placed, the customer buys proprietary consumables for every experiment it runs: sequencing flow cells (ILMN ~$1.3M annual pull-through per NovaSeq X), chromatography columns, cell culture media, filtration membranes, diagnostic test cartridges. Service contracts for maintenance, calibration, and software add another layer. This recurring stream is higher-margin, less cyclical, and constitutes the large majority of revenue.

TMO's largest segment, Lab Products & Biopharma Services (54% of revenue), includes Fisher Scientific distribution—a wholesale channel that ships other companies' lab supplies alongside Thermo's own products. This segment runs at 13% operating margin vs. 36% for Life Sciences Solutions.

TMO: Q1 2025 10-Q, FY2024 earnings release. DHR: MBI Deep Dives (2Q25 update). A: FY2025 10-K, Q2 2026 earnings. ILMN: Q4 2024 earnings call transcript.

Demand

Contracted / observable demand

contracted These companies do not report large contracted backlogs the way defense or infrastructure firms do. Most revenue comes from consumable reorders on short lead times (days to weeks) and instrument orders with 1–6 month delivery cycles. The closest proxies for locked-in demand:

• Installed base pull-through: ILMN's 630 NovaSeq X units (Q4 2024) each generate ~$1.3M/year in consumables = ~$820M/year of near-certain recurring demand from that fleet alone, before the older MiSeq/NextSeq installed base. DHR's Cepheid has ~60,000 installed GeneXpert instruments (flat for five quarters) pulling through test cartridges.
• Service contracts: Agilent CrossLab ($2.9B FY2025 revenue, +6% YoY) is almost entirely multi-year service and consumable agreements tied to an installed instrument base.
• Bioprocessing contracts: DHR's Cytiva/Pall bioprocessing unit (~85% of the Biotechnology segment, which did ~$6.8B in FY2024) sells filtration membranes, chromatography resins, and single-use bags under supply agreements with biopharma manufacturers. Monoclonal antibody customers account for ~75% of bioprocessing consumable revenue. est.

Forecast demand drivers forecast

• Pharma R&D spending: $288B globally in 2024, projected to reach ~$340B by 2030 (Evaluate Pharma). est. Every dollar of pharma R&D eventually flows through instruments and consumables. Growth was +1.5% in 2024, slower than the +11.5% surge in 2023.
• AI-accelerated experiment throughput: As AI generates hypotheses faster, wet labs need to validate more candidates per unit time. This drives higher consumable utilization rates per installed instrument, not necessarily more instrument placements.
• Genomics and multi-omics expansion: Next-generation sequencing is the fastest-growing technology segment at 16.9% CAGR through 2031; proteomics at 13.1% CAGR. Both require specialized instruments and high-margin consumables. est.
• Biopharma pipeline growth: The biologics pipeline (monoclonal antibodies, cell/gene therapies, mRNA) drives demand for bioprocessing equipment and consumables. DHR's bioprocessing consumables grew at low-double-digit rates in Q2 2025.
• China headwind: China represents 7% of ILMN's revenue and a meaningful share for TMO, DHR, and A. All four face trade and regulatory headwinds, including volume-based procurement (VBP) in diagnostics (~$150M DHR impact est.) and ILMN's China Commerce Ministry restrictions. Several companies guided China flat to down.

Pharma R&D: Evaluate Pharma via BioSpace (2024). NGS/proteomics CAGR: Mordor Intelligence (2025). Company data: TMO Q1 2025, DHR Q1 2025, A FY2025, ILMN Q4 2024 / Q1 2025 earnings releases and calls.

Supply

The constraint is oligopoly, not capacity

Unlike data centers or semiconductor fabs, lab instrument manufacturing does not face hard physical capacity bottlenecks. Lead times for most instruments are weeks to months. The constraint is structural: very few companies can make these products, and switching costs keep customers locked in once they adopt a platform.

The oligopoly structure

• Mass spectrometry: TMO (Thermo Scientific), A (Agilent), and Waters (WAT) control the majority of a ~$8B market. est.
• Chromatography: Similar three-way split (TMO, A, Waters) plus Shimadzu (Japan, not US-listed).
• DNA sequencing: ILMN holds ~80% of the global installed base for short-read sequencing. PacBio (PACB) and Oxford Nanopore (UK) compete in long-read but remain small. est.
• Bioprocessing: DHR (Cytiva, Pall), TMO, Sartorius (Germany), and Merck KGaA (Germany) dominate filters, resins, and single-use systems.
• Molecular diagnostics: DHR's Cepheid (~60,000 GeneXpert instruments) leads point-of-care molecular testing. Roche and Abbott compete in centralized labs.

What limits new supply

• Regulatory validation: Clinical and pharmaceutical labs must validate instruments under GLP/GMP/CLIA/CAP standards. Switching a validated instrument to a new vendor's platform takes 6–18 months of re-validation and regulatory filing. This is the single biggest barrier to entry.
• Workflow integration: Instruments connect to proprietary software, LIMS (laboratory information management systems), and downstream analysis pipelines. Customers build years of data, methods, and SOPs around a vendor's ecosystem.
• Consumable lock-in: Most instruments only accept the manufacturer's consumables (ILMN flow cells, Cepheid cartridges, Agilent columns). Third-party alternatives exist for some commodity items but are uncommon for high-end applications.

Market structure from company 10-Ks. Cepheid installed base: DHR 2Q25 update (MBI Deep Dives). ILMN sequencing share: ILMN 10-K disclosures.

The gap

The demand-supply gap here does not look like energy or semiconductors, where physical capacity is the bottleneck. The gap manifests as pricing power from oligopoly structure.

Demand grows at mid-single digits, supply is not physically constrained but is oligopolistically constrained, and the post-COVID destocking headwind that compressed 2023–2024 revenue is now largely behind.

Pharma R&D: Evaluate Pharma. Bioprocessing recovery: DHR Q2 2025 (MBI Deep Dives). Margin trends: TMO FY2024 and A FY2025 earnings releases.

The players

Key differences

• TMO is the largest by revenue ($43B) but carries $46B of goodwill from decades of acquisitions (Fisher Scientific 2006, Life Technologies 2014, PPD 2021). Its Lab Products segment is a distribution business with 13% margins; pure instruments and reagents (Life Sciences Solutions + Analytical Instruments) run at 26–36% operating margins.
• DHR operates the Danaher Business System (DBS), a kaizen-style continuous improvement methodology applied to every acquired company. It spun off Veralto (environmental) in 2023, leaving a pure life sciences and diagnostics company. Bioprocessing (~85% of Biotechnology segment) runs at 40%+ adjusted segment margins with 92% recurring revenue. est.
• A is the smallest diversified player. CrossLab (services + consumables) is the highest-margin segment (32.5% operating margin) and the most recurring. The January 2026 QIAGEN acquisition bid would add a genomics/molecular diagnostics dimension if completed.
• ILMN dominates short-read DNA sequencing with ~80% market share est. but faces a revenue contraction cycle as it transitions customers from NovaSeq 6000 to the lower-per-gigabase-cost NovaSeq X. Consumable revenue grows on volume but declines on price per unit. GRAIL was spun off in June 2024.

All data from company filings: TMO Q1 2025 / FY2024 10-K; DHR Q1 2025 / FY2024 10-K; A FY2025 10-K; ILMN FY2024 / Q1 2025 earnings. Market data: stockanalysis.com, Jun 3 2026. DHR goodwill estimated from FY2024 balance sheet (SageBytes). est. where noted.

The price of exposure

The group trades at 24–34x trailing free cash flow. At 25x FCF, an owner is paying roughly 25 years of current cash generation. If consumable-driven FCF grows at 6–8% per year (roughly in line with the market CAGR est.), that effective entry yield doubles in about a decade. At 3–4% growth (closer to recent pharma R&D growth), the payback period stretches beyond 20 years.

TMO's $31.4B of long-term debt (vs. $5.9B cash) is the most leveraged balance sheet in the group. Most of this debt funded acquisitions whose assets now sit as $46B of goodwill—book value reflects deal premiums, not reproducible asset value. Net-debt-to-FCF is ~3.5x; TMO generates $7.3B of annual FCF against $31B of debt, so it can service the debt, but there is limited margin of safety if FCF contracts.

DHR paused buybacks as of Q2 2025. It has $2.1B cash and declining total assets, consistent with accumulating dry powder for an acquisition.

Market data: stockanalysis.com, Jun 3 2026. FCF, EPS, debt, and cash from most recent filings cited above. Enterprise value = market cap + total debt − cash.

What to deep-dive next

• TMO debt structure: $31.4B of long-term debt across what maturities? What portion is fixed vs. floating? What is the weighted average cost?
• DHR acquisition pipeline: The buyback pause + $2.1B cash + declining total assets suggests dry powder accumulation. A genomics or spatial biology asset would fill a portfolio gap.
• ILMN NovaSeq X transition economics: Lower per-gigabase pricing means consumable revenue per instrument could plateau even as volume grows. Track whether 30%+ annual gigabase growth translates into revenue growth or just price erosion. Monitor the $1.3M/yr pull-through figure over the next 2–3 quarters.
• China exposure quantification: Quantify China revenue as a percentage for each company and model scenarios where China goes to zero.
• AI impact on experiment throughput: Verify whether any of these companies has disclosed accelerating consumable pull-through rates that correlate with AI adoption in their customer base.
• Goodwill impairment risk: TMO carries $46B and DHR ~$40B est. of goodwill. Under what conditions would a write-down be triggered?
• Agilent + QIAGEN: If the acquisition closes, it transforms A's revenue mix toward higher-recurring molecular diagnostics. Verify deal status, price, and financing.

Sources & confidence